University of Texas MD Anderson Cancer Center

Houston, Texas
Professor, Department of Cancer Biology,
Division of Basic Science Research

Research

Dr. Ron DePinho, the recipient of the National Foundation for Cancer Research 2009 Szent-Gyorgyi Prize for Progress in Cancer Research, is working with other scientists on a new drug to target a major signaling protein in over 50% of cancers. The signaling molecule, STAT3, has an integral role in formation of tumors (tumorigenesis) and suppression of our immune system. STAT3 activates transcription – or expression of genes – and therefore controls networks of genes for multiple cellular processes, including proliferation, survival, angiogenesis, metastasis, invasion, and immune escape.

Hyperactivation of STAT3 has been reported in many types of tumors, including head-and neck, brain, breast, liver, lung, kidney, pancreas, prostate, and ovary cancer. STAT3’s key position in cancer signaling as well as in inflammation and fibrosis pathways have been the focus of numerous research and clinical initiatives by the research community to develop effective drugs that target STAT3. Deemed an undruggable molecule, there have been difficulties in developing targeted therapies to STAT3 which include designing stable molecules, creating molecules that can access the inside of cells (membrane permeability) and achieving the optimal dose in tumors to halt tumor growth.

Using computer-based drug screening of hundreds of thousands of compounds from chemical libraries, the scientists have identified several compounds that inhibit STAT3 protein in complex tumor models of various cancer types.

With NFCR support, their efforts have led to a promising therapeutic now being commercialized by the AIM-HI Translational Research Initiative. To learn more, click here.

Bio

Dr. Ronald A. DePinho was the fourth president of The University of Texas MD Anderson Cancer Center, serving from 2012 to 2018 prior to his current position as Professor, Department of Cancer Biology, Division of Basic Science Research, and the Harry Graves Burkhart III Distinguished University Chair in Cancer Biology. Dr. DePinho was a professor of Medicine (Genetics) at Harvard Medical School from 1998 to 2011. He received his M.D. from Albert Einstein College of Medicine in 1981 and began his academic career where he rose to Professor, Department of Departments of Microbiology & Immunology, and Medicine.

Dr. DePinho is an elected member of the National Academy of Medicine; National Academy of Science; Foreign Member, Royal Academy of Science, Portugal; among other memberships in prestigious institutions. In addition to the Szent-Gyorgyi Prize for Progress in Cancer Research, he has received numerous awards including the Biomedicum Helsinki Medal and Lecture, Harvey Society Lecture, and the Prize for Scientific Excellence in Medicine, American Italian Cancer Foundation. His community service includes Member, Steering Committee, National Cancer Institute, Co-Chair, External Advisory Board, The Human Cancer Genome Atlas Project, and numerous cancer society memberships. Dr. DePinho is the author of over 400 publications.

Related Content

Don’t Delay: Skipping One Mammogram Can Significantly Increase Risk of Death from Breast Cancer

One mammogram every two years doesn’t sound so bad – but what happens if a woman skips one? A recent study warns that missing just one mammogram before being diagnosed with cancer significantly increases a woman’s probability of dying from the disease.  The Importance of Mammograms Mammograms allow medical professionals to examine an x-ray of the breast tissue and look for any abnormalities or hints of cancer that other methods may not be able to detect. Having regularly scheduled mammograms presents an opportunity for early diagnosis, which significantly increases the ability to administer successful treatment. As signs and symptoms are often difficult to observe at early stages, mammograms have been the gold standard used for cancer detection and may reduce mortality by up to 40%. Because of this, the United States Preventative Services Task Force recommends that women aged 50-74 undergo a mammography every two years. Alarming Study Results In this ground-breaking study, a research team led by Stephen W. Duffy and Laszlo Tabar analyzed data from nearly 550,000 women with access to mammograms between 1992 and 2016. This data was divided into two groups – women who attended the two of the most recent mammograms before being diagnosed with breast cancer and those who did not.  The team discovered that the group who did not attend the two most recent mammograms before their diagnosis were more likely to have died within ten years of being diagnosed. The significant findings showed that 50% more of these group members had died than those who attended both most recent appointments. Overall, women who attended only one of the two breast cancer screenings had 29% higher mortality than those who attended both. While the research team anticipated a higher mortality rate among women who missed even one mammogram before their diagnosis, the disparity was astounding. As researchers unveil more evidence to highlight the importance of mammograms, however, medical professionals continue to identify a decrease in the number of women who undertake regular screenings. Tragically, the COVID-19 pandemic has also caused a significant decline in the number of women attending their regular mammograms.  What Next? Duffy, Laszlo, and their team hope their recent findings will inspire women to keep up-to-date with their mammogram appointments and plan to continue further prognostic research into the mechanisms of this effect. The team will explore to what extent regular attendance improves the prognosis of interval cancers and screen-detected cancers.  While the world eagerly awaits the following report, women must continue adhering to the current mammogram recommendations. Those with questions regarding their personal situation and recommendations should speak to their general practitioner.  For more information regarding breast cancer, please visit NFCR’s breast cancer page.  Note: The third Friday in October we recognize National Mammography Day. This year it will be celebrated on October 15, 2021. Please take this opportunity to schedule your mammogram or share important information with loved ones. Additional Reads You May Enjoy: Let’s talk about Mammograms with Dr. Alexia Matheson National Mammography Day 5 Ways You Can Show Support for Breast Cancer Patients Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Controlling the Uncontrollable: HER2 Breast Cancer

It’s that time of year when pink ribbons begin appearing everywhere – from shopfronts to social media. These ribbons are known to be Breast Cancer Awareness ribbons. It’s no coincidence that pink ribbons are the most easily recognized as breast cancer is the most common cancer in women worldwide. In fact, one in eight women will be diagnosed with breast cancer.  Tragically, the likelihood of experiencing metastasis, or cancer that spreads to other parts of the body, is high amongst these patients. Understanding and preventing metastasis is crucial to increasing the survival rates of this disease. Thankfully, National Foundation for Cancer Research (NFCR)-funded researcher Dr. Rakesh K. Jain and his team are dedicated to exploring this phenomenon and recently unearthed a game-changing discovery.  Their mission: HER2 Dr. Jain and his team knew that genes contain the recipes for various proteins required for healthy cells to function properly and that some genes and proteins can influence how breast cancer behaves and responds to treatment. They were particularly interested in exploring how to control and inhibit metastasis in one particular gene related to breast cancer, the HER2 gene.  The HER2 (human epidermal growth factor receptor 2) gene makes HER2 proteins, which are receptors on breast cells. Typically, HER2 receptors help control how a healthy breast cell grows, divides, and repairs itself. But in about 10% to 20% of breast cancers, the HER2 gene doesn’t work correctly and makes too many copies of itself (known as HER2 gene amplification). These extra HER2 genes tell breast cells to make too many HER2 receptors which makes breast cells grow and divide in an uncontrolled way. Patients with metastatic HER2+ breast cancer often experience treatment resistance, disease recurrences, and metastases. Dr. Jain and his team believed that by modifying the tumor framework and increasing oxygenation in the tumor, it might be possible for an existing medication to improve the outcome of radiotherapy and inhibit disease progression in a highly metastatic HER2+ breast cancer. Their findings The team established a metastatic HER2+ breast cancer line and used it to generate a similar environment in mice. Three days after tumor implantation, Dr. Jain and his team administered seven days of Losartan, a drug mainly used to treat high blood pressure. In some mice, the research team followed the seven days of Losartan with 20 Gy single dose local irradiation on day 10. In a third group, they followed the seven days of Losartan with 20 Gy fractionated irradiation on days 10-14. For each group, the researchers analyzed the tumor-growth delay, development of metastases, survival rates, tumor density, and oxygen levels in the tumor.  Much to the excitement of cancer researchers worldwide, the combination of Losartan and local irradiation significantly enhanced tumor response. The tumors were deprived of oxygen, whereas healthy cells remained oxygen-rich. This finding suggests that combining Losartan with radiotherapy is a potential new treatment strategy for controlling and inhibiting metastasis in HER2+ breast cancer – a potentially life-saving discovery. Other exciting HER2 discoveries  HER2 has been a hot topic in the cancer world for years. In fact, Dr. Jain is just one of the NFCR-funded researchers paving the way to better treatment options related to HER2. Dr. […]

New Treatment with Combined Immunotherapies is Effective for Drug Resistant Metastatic Lung Cancer